Literature DB >> 12729137

Evaluation of the efficacy of a nonlatex condom: results from a randomized, controlled clinical trial.

Terri L Walsh1, Ron G Frezieres, Karen Peacock, Anita L Nelson, Virginia A Clark, Leslie Bernstein.   

Abstract

CONTEXT: To reduce unintended pregnancy and HIV infection, it is critical to develop reliable male condoms that will attract consumers who reject conventional latex condoms.
METHODS: In a prospective clinical trial conducted in 1998-2000, 830 monogamous couples were randomized in equal numbers to use either a nonlatex condom or a commercial natural latex condom for six months as their only method of birth control. Couples completed detailed reports for the first five condom uses and recorded intercourse and condom use in coital diaries. Pregnancy rates associated with typical and consistent condom use were calculated using life-table analysis. Rates of clinical failure (condom breakage or slippage) were determined for the first five condom uses.
RESULTS: During the first five uses, the nonlatex condom had a higher frequency of breakage or slippage during intercourse or withdrawal (4.0%) than latex condoms (1.3%); the breakage rate for the nonlatex condom was about eight times that of latex condoms. The six-cycle typical-use pregnancy rate did not differ significantly between users of nonlatex (10.8%) and latex condoms (6.4%). The six-cycle consistent-use pregnancy rate was higher for nonlatex condom users than for latex condom users (4.9% vs. 1.0%).
CONCLUSIONS: The data present strong indirect support for public health messages that promote the use of latex condoms and, for individuals who cannot or are unwilling to use latex condoms, the use of nonlatex condoms for prevention of pregnancy and disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729137

Source DB:  PubMed          Journal:  Perspect Sex Reprod Health        ISSN: 1538-6341


  10 in total

1.  Validation of an Event-Level, Male Sexual Pleasure Scale (EMSEXpleasure) Among Condom-Using Men in the U.S.

Authors:  Aaron J Siegler; Elizabeth Boos; Eli S Rosenberg; Michael P Cecil; Patrick S Sullivan
Journal:  Arch Sex Behav       Date:  2018-02-01

Review 2.  Contraceptive failure in the United States.

Authors:  James Trussell
Journal:  Contraception       Date:  2011-03-12       Impact factor: 3.375

Review 3.  Complementary and alternative medicines: the herbal male contraceptives.

Authors:  Fanuel Lampiao
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-07-03

Review 4.  Male contraception.

Authors:  John K Amory
Journal:  Fertil Steril       Date:  2016-09-24       Impact factor: 7.329

Review 5.  Understanding contraceptive failure.

Authors:  James Trussell
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2009-02-14       Impact factor: 5.237

Review 6.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 7.  Nanotechnology and the future of condoms in the prevention of sexually transmitted infections.

Authors:  Clarence S Yah; Geoffrey S Simate; Percy Hlangothi; Benesh M Somai
Journal:  Ann Afr Med       Date:  2018 Apr-Jun

Review 8.  Development of Novel Male Contraceptives.

Authors:  John K Amory
Journal:  Clin Transl Sci       Date:  2019-11-14       Impact factor: 4.689

9.  Participant characteristics associated with withdrawal from a large randomized trial of spermicide effectiveness.

Authors:  Elizabeth G Raymond; Pai Lien Chen; Bosny Pierre-Louis; Joanne Luoto; Kurt T Barnhart; Lynn Bradley; Mitchell D Creinin; Alfred Poindexter; Livia Wan; Mark Martens; Robert Schenken; Cate F Nicholas; Richard Blackwell
Journal:  BMC Med Res Methodol       Date:  2004-10-01       Impact factor: 4.615

10.  Efficacy of a combined contraceptive regimen consisting of condoms and emergency contraception pills.

Authors:  Rui Zhao; Jun-Qing Wu; Yu-Yan Li; Ying Zhou; Hong-Lei Ji; Yi-Ran Li
Journal:  BMC Public Health       Date:  2014-04-14       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.